Leveron 500 Tablet

About Leveron 500 Tablet

Leveron 500 is a tablet containing levetiracetam, an anti-epileptic medicine that helps control certain types of seizures by acting on the brain's nerve signals. It is used as part of a treatment plan set by your doctor.

There are 34 brands of Levetiracetam listed in Bangladesh. The lowest listed price is Citazar 250 mg Tablet at ৳ 15.11 per unit.

What is Leveron 500 Tablet?

Leveron 500 is a 500 mg tablet made by Synovia Pharma PLC. It contains levetiracetam, which belongs to a group of medicines called anti-epileptics. These medicines work on the electrical activity in the brain to help reduce the chance of seizures. Levetiracetam is used both alone and alongside other epilepsy medicines in different age groups, depending on what the doctor decides. Leveron 500 is a prescription medicine, so it should only be taken on a doctor's advice. The doctor will choose whether it is suitable for you and how long you need to take it.

Uses of Leveron 500

Leveron 500 is used to treat partial-onset seizures, which are seizures that start in one part of the brain. It may be used on its own in some people with newly diagnosed epilepsy, or together with other epilepsy medicines in adults, adolescents, children and infants. The doctor decides which use applies to each person. It is not a general treatment for all types of seizures, so ask the doctor if you are unsure why it has been prescribed.

How to use Leveron 500

Take Leveron 500 exactly as the doctor tells you. The doctor decides the dose and how long the course should last, and may adjust it over time based on how you respond. Swallow the tablet as advised by your doctor or pharmacist. Do not stop taking it suddenly on your own, because stopping epilepsy medicine without medical advice can be harmful. If you miss a dose, ask your doctor or pharmacist what to do. Keep all follow-up appointments so your doctor can check how the medicine is working.

Side effects of Leveron 500

Some people feel sleepy, weak or dizzy while taking levetiracetam. In children, tiredness, aggression, nasal congestion, decreased appetite and irritability have been reported. These effects are not experienced by everyone. Tell your doctor if any side effect bothers you or does not go away. Get medical help promptly if you notice unusual bruising or bleeding, signs of infection such as fever, or a severe reaction, as these need to be checked. Do not change your dose without speaking to your doctor first.

Safety and precautions

Tell your doctor about any kidney or liver problems before starting Leveron 500, because the dose may need to be adjusted. It is not recommended during pregnancy, or in women who could become pregnant and are not using contraception, unless the doctor decides it is clearly necessary. It passes into breast milk, so breastfeeding is generally not recommended unless the doctor advises otherwise. Do not use it if you are allergic to levetiracetam or similar medicines. Ask your doctor first if you have any health concerns or take other medicines.

Frequently asked questions

What is Leveron 500 used for and what kind of medicine is it?

Leveron 500 is an anti-epileptic tablet containing levetiracetam. It is used to help control partial-onset seizures, either alone or with other epilepsy medicines, depending on the doctor's assessment. It is a prescription medicine, so only your doctor can decide if it is right for you.

What side effects should I watch for, and when should I call the doctor?

Sleepiness, weakness and dizziness are among the more common effects in adults. Children may show tiredness, aggression, irritability or reduced appetite. Call your doctor if these are troublesome, or seek help promptly for unusual bruising or bleeding, fever or signs of infection, or any severe reaction.

How should Leveron 500 be stored?

Keep the tablets in a cool, dry place away from light, and do not store them above the temperature your pharmacist advises. Keep them out of reach of children. Do not use tablets after the expiry date shown on the pack. If you are unsure how to store them, ask your pharmacist.

Can I stop taking Leveron 500 on my own?

No. Stopping epilepsy medicine suddenly without medical advice can be harmful. Your doctor decides the dose and how long you need to take it, and will tell you how to stop safely if that becomes necessary. Speak to your doctor before making any change.

Indications

Levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Levetiracetam is indicated as adjunctive therapy-
  • in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
  • ... Read more
Levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Levetiracetam is indicated as adjunctive therapy-
  • in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
  • in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
  • in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Dosage & Administration

Adults and adolescents from 16 years of age: The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.

Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.

Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.

  • Monotherapy: The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
  • Add-on therapy: Oral solution is the preferred formulation for use in infants and children under the age of 6 years. For children 6 years and above, oral solution should be used for doses under 250 mg, for doses not in multiples of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dosing for children 50 kg or greater is the same as in adults.
  • Add-on therapy: For infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in infants.

Interaction

Antiepileptic medicinal products: Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.

Probenecid: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.

Methotrexate: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.

Laxatives: There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.

Food and alcohol: The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available.

Contraindications

Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients.

Side Effects

Most common adverse reactions (incidence ≥ 5% more than placebo) include:
  • Adult patients: somnolence, asthenia, infection and dizziness
  • Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability

Pregnancy & Lactation

Levetiracetam is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary. Levetiracetam is excreted in human breast milk. Therefore, breastfeeding is not recommended. However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding. No impact on fertility was detected in animal studies. No clinical data are available, the potential risk for humans is unknown.

Precautions & Warnings

Renal impairment: The administration of levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection.

Acute kidney injury: The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.

Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders.

Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.

Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest an impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.

Overdose Effects

Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses. After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. There is no specifc antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60 % for levetiracetam and 74% for the primary metabolite.

Storage Conditions

Store at a cool temperature (not exceeding 25°C) and dry place, protected from light.

Alternative brands of Levetiracetam

Other brands with the same generic name, cheapest first.

Citazar Tablet

250 mg

Levetiracetam

Advanced Chemical Industries PLC

৳ 14.81 ৳ 15.11 2% off per unit

Iracet Tablet

250 mg

Levetiracetam

Square Pharmaceuticals PLC.

৳ 15.68 ৳ 16.00 2% off per unit

Citazar Tablet

500 mg

Levetiracetam

Advanced Chemical Industries PLC

৳ 29.4 ৳ 30.00 2% off per unit

Iracet Tablet

500 mg

Levetiracetam

Square Pharmaceuticals PLC.

৳ 31.36 ৳ 32.00 2% off per unit

See all 34 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.